Search

Your search keyword '"Ramaswamy, M."' showing total 835 results
Start Over Author "Ramaswamy, M."
835 results on '"Ramaswamy, M."'

2. Motion of a rigid body in a compressible Fluid with Navier-slip boundary condition

Author

Necasova, S., Ramaswamy, M., Roy, A., and Schlomerkemper, A.

Subjects
Mathematics - Analysis of PDEs, 35Q30, 76N10
Abstract

In this work, we study the motion of a rigid body in a bounded domain which is filled with a compressible isentropic fluid. We consider the Navier-slip boundary condition at the interface as well as at the boundary of the domain. This is the first mathematical analysis of a compressible fluid-rigid body system where Navier-slip boundary conditions are considered. We prove existence of a weak solution of the fluid-structure system up to collision.

Published
2021

3. Injectable and biodegradable piezoelectric hydrogel for osteoarthritis treatment

Author

Tra Vinikoor, Godwin K. Dzidotor, Thinh T. Le, Yang Liu, Ho-Man Kan, Srimanta Barui, Meysam T. Chorsi, Eli J. Curry, Emily Reinhardt, Hanzhang Wang, Parbeen Singh, Marc A. Merriman, Ethan D’Orio, Jinyoung Park, Shuyang Xiao, James H. Chapman, Feng Lin, Cao-Sang Truong, Somasundaram Prasadh, Lisa Chuba, Shaelyn Killoh, Seok-Woo Lee, Qian Wu, Ramaswamy M. Chidambaram, Kevin W. H. Lo, Cato T. Laurencin, and Thanh D. Nguyen

Subjects
Science
Abstract

Abstract Osteoarthritis affects millions of people worldwide but current treatments using analgesics or anti-inflammatory drugs only alleviate symptoms of this disease. Here, we present an injectable, biodegradable piezoelectric hydrogel, made of short electrospun poly-L-lactic acid nanofibers embedded inside a collagen matrix, which can be injected into the joints and self-produce localized electrical cues under ultrasound activation to drive cartilage healing. In vitro, data shows that the piezoelectric hydrogel with ultrasound can enhance cell migration and induce stem cells to secrete TGF-β1, which promotes chondrogenesis. In vivo, the rabbits with osteochondral critical-size defects receiving the ultrasound-activated piezoelectric hydrogel show increased subchondral bone formation, improved hyaline-cartilage structure, and good mechanical properties, close to healthy native cartilage. This piezoelectric hydrogel is not only useful for cartilage healing but also potentially applicable to other tissue regeneration, offering a significant impact on the field of regenerative tissue engineering.

Published
2023
Full Text
View/download PDF

8. Modeling of Brushless DC Motor Using Adaptive Control

Author

Veeramuthulingam, N., Ezhilarasi, A., Ramaswamy, M., Muthukumar, P., Barbosa, Simone Diniz Junqueira, Series Editor, Filipe, Joaquim, Series Editor, Kotenko, Igor, Series Editor, Sivalingam, Krishna M., Series Editor, Washio, Takashi, Series Editor, Yuan, Junsong, Series Editor, Zhou, Lizhu, Series Editor, Zelinka, Ivan, editor, Senkerik, Roman, editor, Panda, Ganapati, editor, and Lekshmi Kanthan, Padma Suresh, editor

Published
2018
Full Text
View/download PDF

9. Clustered Heed Based Cross Layer Routing Scheme for Performance Enhancement of Cognitive Radio Sensor Networks

Author

Janani, S., Ramaswamy, M., Samuel Manoharan, J., Barbosa, Simone Diniz Junqueira, Series Editor, Filipe, Joaquim, Series Editor, Kotenko, Igor, Series Editor, Sivalingam, Krishna M., Series Editor, Washio, Takashi, Series Editor, Yuan, Junsong, Series Editor, Zhou, Lizhu, Series Editor, Zelinka, Ivan, editor, Senkerik, Roman, editor, Panda, Ganapati, editor, and Lekshmi Kanthan, Padma Suresh, editor

Published
2018
Full Text
View/download PDF

10. Spectrum Sensing Based Heed Routing Performance Enhancement Strategy for Cognitive Radio Sensor Networks

Author

Janani, S., Ramaswamy, M., Samuel Manoharan, J., Barbosa, Simone Diniz Junqueira, Series editor, Chen, Phoebe, Series editor, Filipe, Joaquim, Series editor, Kotenko, Igor, Series editor, Sivalingam, Krishna M., Series editor, Washio, Takashi, Series editor, Yuan, Junsong, Series editor, Zhou, Lizhu, Series editor, Venkataramani, Guru Prasadh, editor, Sankaranarayanan, Karthik, editor, Mukherjee, Saswati, editor, Arputharaj, Kannan, editor, and Sankara Narayanan, Swamynathan, editor

Published
2018
Full Text
View/download PDF

11. Injectable and biodegradable piezoelectric hydrogel for osteoarthritis treatment

Author

Vinikoor, Tra, primary, Dzidotor, Godwin K., additional, Le, Thinh T., additional, Liu, Yang, additional, Kan, Ho-Man, additional, Barui, Srimanta, additional, Chorsi, Meysam T., additional, Curry, Eli J., additional, Reinhardt, Emily, additional, Wang, Hanzhang, additional, Singh, Parbeen, additional, Merriman, Marc A., additional, D’Orio, Ethan, additional, Park, Jinyoung, additional, Xiao, Shuyang, additional, Chapman, James H., additional, Lin, Feng, additional, Truong, Cao-Sang, additional, Prasadh, Somasundaram, additional, Chuba, Lisa, additional, Killoh, Shaelyn, additional, Lee, Seok-Woo, additional, Wu, Qian, additional, Chidambaram, Ramaswamy M., additional, Lo, Kevin W. H., additional, Laurencin, Cato T., additional, and Nguyen, Thanh D., additional

Published
2023
Full Text
View/download PDF

14. OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS

Author

Jayne, D., primary, Gavin, P., additional, Allman, E., additional, Di Poto, C., additional, Tian, X., additional, Hess, S., additional, Ramaswamy, M., additional, Lazarus, M., additional, Brohawn, P. Z., additional, Muthas, D., additional, Platt, A., additional, Al-Mossawi, H., additional, Lindholm, C., additional, and Ferrari, N., additional

Published
2023
Full Text
View/download PDF

16. Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis

Author

Maher, TM, Ford, P, Brown, KK, Costabel, U, Cottin, V, Danoff, SK, Groenveld, I, Helmer, E, Jenkins, RG, Milner, J, Molenberghs, G, Penninckx, B, Randall, MJ, Van Den Blink, B, Fieuw, A, Vandenrijn, C, Rocak, S, Seghers, I, Shao, L, Taneja, A, Jentsch, G, Watkins, TR, Wuyts, WA, Kreuter, M, Verbruggen, N, Prasad, N, Wijsenbeek, MS, Chambers, D, Chia, M, Corte, T, Glaspole, I, Goh, N, Holmes, M, Malouf, M, Thien, F, Veitch, E, Bondue, B, Dahlqvist, C, Froidure, A, Slabbynck, H, Wuyts, W, Cartagena Salinas, C, Feijoó Seoane, R, Martínez, V, Maturana, R, Pavie Gallegos, J, Rosenblut, A, Silva, R, Undurraga Pereira, A, Doubkova, M, Pauk, N, Plackova, M, Sterclova, M, Bendstrup, E, Shaker, SB, Titlestad, I, Budweiser, S, Grohé, C, Koschel, D, Prasse, A, Weber, M, Wirtz, H, Antoniou, K, Daniil, Z, Gaga, M, Papakosta, D, Izumi, S, Okamoto, M, Guerreros Benavides, A, Iberico Barrera, C, Peña Villalobos, AM, Campo Ezquibela, A, Cifrian Martinez, JM, Fernandez Fabrellas, E, Leiro, V, Molina-Molina, M, Nieto Barbero, A, Sellares Torres, J, Valenzuela, C, Cheng, S-L, Kuo, P-H, Lee, K-Y, Sheu, C-C, Gunen, H, Mogulkoc Bishop, N, Nayci, S, Adamali, H, Bianchi, S, Chaudhuri, N, Gibbons, M, Hart, S, Molyneaux, P, Parfrey, H, Saini, G, Spencer, LG, Wiscombe, S, Antin-Ozerkis, D, Bascom, R, Belperio, J, Britt, E, Fitzgerald, J, Gomez Manjarres, D, Gotfried, M, Gupta, N, Hotchkin, D, Kaye, M, Kreider, M, Kureishy, S, Lacamera, P, Lancaster, L, Lasky, J, Lorch, D, Mannem, H, Morrow, L, Moua, T, Nambiar, A, Raghu, G, Raj, R, Ramaswamy, M, Reddy, R, Russell, T, Scholand, MB, Shea, B, Suliman, S, Swigris, J, Thavarajah, K, Tolle, L, Tomic, R, Warshoff, N, Wesselius, L, Yung, G, Bergna, M, De Salvo, M, Fernandez Acquier, M, Rodriguez, A, Saez Scherbovsky, P, Assayag, D, Dhar, A, Khalil, N, Morisset, J, Provencher, S, Ryerson, C, Shapera, S, Bourdin, A, Crestani, B, Lebargy, F, Reynaud-Gaubert, M, Bonella, FT, Claussen, M, Hammerl, P, Karagiannidis, C, Keller, C, Randerath, W, Stubbe, B, Csánky, E, Medgyasszay, B, Muller, V, Adir, Y, Bar-Shai, A, Berkman, N, Fink, G, Kramer, M, Shitrit, D, Bargagli, E, Gasparini, S, Harari, S, Ravaglia, C, Richeldi, L, Vancheri, C, Ebina, M, Fujita, M, Ichikado, K, Inoue, Y, Ishikawa, N, Kato, M, Kawamura, T, Kondoh, Y, Nishioka, Y, Ogura, T, Owan, I, Saito, T, Sakamoto, N, Sakamoto, K, Shirai, M, Suda, T, Tomii, K, Chung, MP, Jeong, SH, Park, CS, Park, JS, Song, JW, Uh, S-T, Chavarria Martinez, U, Montano Gonzalez, E, Ramirez, A, Selman Lama, ME, Bresser, P, Kramer, H, Mostard, R, Nossent, E, Veltkamp, M, Wijsenbeek, M, Beckert, L, Chang, CL, Veale, A, Wilsher, M, Bednarek, M, Gasior, G, Jasieniak-Pinis, G, Jassem, E, Mroz, R, Piotrowski, W, Abdullah, I, Ambaram, A, Irusen, E, Van der Linden, M, Van Zyl-Smit, R, Williams, P, Allen, J, Averill, F, Belloli, E, Brown, A, Case, A, Chaudhary, S, Criner, G, DeBoer, K, Dilling, D, Dorf, J, Enelow, R, Ettinger, N, Feldman, J, Gibson, K, Golden, J, Hamblin, M, Hunninghake, G, Karunakara, R, Kim, H, Luckhardt, T, Menon, P, Morrison, L, Oldham, J, Patel, N, Schmidt, S, Strek, M, Summer, R, Sussman, R, Tita, J, Veeraraghavan, S, Whelan, T, and Zibrak, J

Abstract

Importance There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor ziritaxestat in patients with IPF. Design, Setting, and Participants The 2 identically designed, phase 3, randomized clinical trials, ISABELA 1 and ISABELA 2, were conducted in Africa, Asia-Pacific region, Europe, Latin America, the Middle East, and North America (26 countries). A total of 1306 patients with IPF were randomized (525 patients at 106 sites in ISABELA 1 and 781 patients at 121 sites in ISABELA 2). Enrollment began in November 2018 in both trials and follow-up was completed early due to study termination on April 12, 2021, for ISABELA 1 and on March 30, 2021, for ISABELA 2. Interventions Patients were randomized 1:1:1 to receive 600 mg of oral ziritaxestat, 200 mg of ziritaxestat, or placebo once daily in addition to local standard of care (pirfenidone, nintedanib, or neither) for at least 52 weeks. Main Outcomes and Measures The primary outcome was the annual rate of decline for forced vital capacity (FVC) at week 52. The key secondary outcomes were disease progression, time to first respiratory-related hospitalization, and change from baseline in St George’s Respiratory Questionnaire total score (range, 0 to 100; higher scores indicate poorer health-related quality of life). Results At the time of study termination, 525 patients were randomized in ISABELA 1 and 781 patients in ISABELA 2 (mean age: 70.0 [SD, 7.2] years in ISABELA 1 and 69.8 [SD, 7.1] years in ISABELA 2; male: 82.4% and 81.2%, respectively). The trials were terminated early after an independent data and safety monitoring committee concluded that the benefit to risk profile of ziritaxestat no longer supported their continuation. Ziritaxestat did not improve the annual rate of FVC decline vs placebo in either study. In ISABELA 1, the least-squares mean annual rate of FVC decline was –124.6 mL (95% CI, −178.0 to −71.2 mL) with 600 mg of ziritaxestat vs –147.3 mL (95% CI, −199.8 to −94.7 mL) with placebo (between-group difference, 22.7 mL [95% CI, −52.3 to 97.6 mL]), and –173.9 mL (95% CI, −225.7 to −122.2 mL) with 200 mg of ziritaxestat (between-group difference vs placebo, −26.7 mL [95% CI, −100.5 to 47.1 mL]). In ISABELA 2, the least-squares mean annual rate of FVC decline was –173.8 mL (95% CI, −209.2 to −138.4 mL) with 600 mg of ziritaxestat vs –176.6 mL (95% CI, −211.4 to −141.8 mL) with placebo (between-group difference, 2.8 mL [95% CI, −46.9 to 52.4 mL]) and –174.9 mL (95% CI, −209.5 to −140.2 mL) with 200 mg of ziritaxestat (between-group difference vs placebo, 1.7 mL [95% CI, −47.4 to 50.8 mL]). There was no benefit with ziritaxestat vs placebo for the key secondary outcomes. In ISABELA 1, all-cause mortality was 8.0% with 600 mg of ziritaxestat, 4.6% with 200 mg of ziritaxestat, and 6.3% with placebo; in ISABELA 2, it was 9.3% with 600 mg of ziritaxestat, 8.5% with 200 mg of ziritaxestat, and 4.7% with placebo. Conclusions and Relevance Ziritaxestat did not improve clinical outcomes compared with placebo in patients with IPF receiving standard of care treatment with pirfenidone or nintedanib or in those not receiving standard of care treatment. Trial Registration ClinicalTrials.gov Identifiers: NCT03711162 and NCT03733444

Published
2023

23. A new reduced switch count symmetrical and asymmetrical modular topology for multilevel inverters

Author

Anusuya, M., Geetha, R., and Ramaswamy, M.

Abstract

The paper proposes two new topologies for single phase multilevel inverters (MLIs) to operate both in the symmetrical and asymmetrical configurations with a view at lowering the number of switching devices in the path for the flow of the current. It involves a mathematical interpretation to determine the magnitude of the voltage sources in an effort to configure the proposed topology in the asymmetrical configuration and obtain higher number of voltage levels. It engages the principles of carrierless pulse width modulation (PWM) for extracting the shape of the output voltage waveform to a nearly sinusoidal form and there by improve the quality of the power delivered to the load. The procedure owes to analyse the operating modes of both the topologies in MATLAB/Simulink platform and includes an experimental prototype to validate the simulation results.

Published
2024
Full Text
View/download PDF

24. PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis

Author

Lindholm, C, primary, Brunner, HI, additional, Cody, E, additional, Devarajan, P, additional, Huang, B, additional, Sinibaldi, D, additional, Ramaswamy, M, additional, Knagenhjelm, J, additional, Qiu, T, additional, Jones, F, additional, Brohawn, PZ, additional, Tummala, R, additional, and White, WI, additional

Published
2022
Full Text
View/download PDF

27. POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Author

Cody, E., primary, Brunner, H., additional, Huang, B., additional, Qiu, T., additional, Devarajan, P., additional, Ramaswamy, M., additional, Sinibaldi, D., additional, Brohawn, P. Z., additional, Knagenhjelm, J., additional, Jones, F., additional, Tummala, R., additional, Lindholm, C., additional, and White, W., additional

Published
2022
Full Text
View/download PDF

38. Profile Of Sexually Transmitted Diseases In A Clinic In The Suburb Of Kolkata (West Bengal)

Author

Jaiswal A K, Chatterjee M, Walia N, Bal A S, and Ramaswamy M S

Subjects
Dermatology, RL1-803
Abstract

Records of new STD patients attending the Base Hospital, Barrackpore, near Kolkata between 1991 and 2000 were analysed to examine the pattern of STDs among them. Among 567 new STD patients examined, syphilis predominated, followed by gonorrhoea, chancroid, genital warts, lymphogramuloma venereum and herpes genitalis. Non- gonococcal urethritis constituted 4.2% of study population. The overall HIV seropositivity showed a rising treads in the recent past.

Published
2003

47. Case of an Accessory Cavitated Uterine Malformation (ACUM).

Author

Ramaswamy, M, Youssef, Y, Azar, O, and Bral, P

Abstract

The purpose of this video is to present a case of an Accessory Cavitated Uterine Malformation. Video footage illustrating the surgical removal of a uterine accessory cavity. Tertiary referral center. A 19 yo gravida 0 who presented with pelvic pain for several years, worse with menses. A pre-operative pelvic ultrasound suggested a degenerating myoma measuring 2.8cm as the cause of her pelvic pain. Pathology confirmed presence of endometrial glands within muscle cells. Robotic assisted laparoscopic removal of accessory cavity. This involved injecting diluted vasopressin to the base of the accessory mass for vasoconstriction prior to incision and dissection, and suture of defect. Resolution of pelvic pain in the patient 2 months post-operative Accessory Cavitated Uterine Malformation is an unclassified Mullerian anomaly of unknown true incidence. Surgical Excision can provide resolution of symptoms of pelvic pain. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results